Scientific Online Resource System

Health Economics and Management

Analysis and assessment of the bulgarian pharmaceutical industry for manufacturing of medicinal products in human use

Galina Petrova, Valentina Belcheva, Evgeni Grigorov

Abstract

One of the main activities related to the provision of medicines is their production. Historically, it has been performing in the pharmacies over a very long period of time. After the beginning of the economic revolution and the initiation of the industrial production of the commodity, a separate drug manufacturing has appeared. To this moment, it is considered a self-sustaining branch of special importance for the system of health.
Participants in the pharmaceutical industry in Bulgaria are local and foreign companies that have invested in the manufacture of medicines and active substances. The article examines and analyzes the manufacturers/importers registered in the territory of our country with respect to the main types of dosage forms – sterile, non-sterile medicinal products, biological drugs, clinical trial медицинес, infusion solutions and the type of packaging, storage, certification and release. The economic zones/regions for planning in Bulgaria were used as a comparison. The interconnection between the planning regions and the number of production facilities has also been investigated.

Keywords

analysis; assessment; Bulgarian pharmaceutical industry; manufacturing of medicinal products; human use

Full Text


References

Troy DB, Remington JP, Beringer P. Remington: The Science and Practice of Pharmacy. Lippincott Williams & Wilkins; 2006. (REMINGTON THE SCIENCE AND PRACTICE OF PHARMACY).

Lincker H, Ziogas C, Carr M, Porta N, Eichler H-G. Regulatory watch: Where do new medicines originate from in the EU? Nat Rev Drug Discov. 2014 Feb;13(2):92–3.

Kneller R. The importance of new companies for drug discovery: origins of a decade of new drugs. Nat Rev Drug Discov. 2010 Nov;9(11):867–82.

Agrawal M. Global Competitiveness in the Pharmaceutical Industry: The Effect of National Regulatory, Economic, and Market Factors. Taylor & Francis; 1999.

Reinhardt UE. The Pharmaceutical Sector in Health Care. In: Sloan FA, Hsieh C-R, editors. Pharmaceutical Innovation. Cambridge: Cambridge University Press; 2007. p. 25–53.

Lebanova H, Manolov D, Getov I. Patients’ attitude about generics – Bulgarian perspective. Marmara Pharm Jounal. 2012;16(1):36–40.

Lakdawalla DN. Economics of the pharmaceutical industry. J Econ Lit. 2018; 56(2):397–449.

Гергова В, Стоименова А, Спиров С, Гетова В. Статут и комтепентност на националните лекарствени агенции в ЕС. Социална медицина. 2017;25(2–3):60–3.

Malerba F, Orsenigo L. The evolution of the pharmaceutical industry. Bus Hist. 2015 Jul;57(5):664–87.

Dickov V, Mitrovic D, Kuzman B. Analyzing pharmaceutical industry. Natl J Physiol Pharm Pharmacol. 2011;1(1):1.

Финков Т, Издебски П, Салчев П. Тенденции в устойчивия пазар на лекарствени средства. Българско списание за обществено здраве. 2017;9(4):40–51.

НС. Закон за лекарствените продукти в хуманната медицина. 2007.

Stoimenova AH, Kirilov BJ, Gueorguiev SR, Petkova-Gueorguieva ES, Ognianov SG. Good Manufacturing Practice for Medicinal Products in Bulgaria: an Analysis of Regulatory Inspection Findings. Folia Med (Plovdiv). 2020 Mar 31; 62(1):165–71.

Веков Т. Социална фармация и фармацевтично законодателство. Медицински университет Плевен; 2014.

Петрова Г, Петкова В, Гетов И, Стоименова А, Савова А, Манова М, и кол. Социална фармация и фармацевтично законодателство. 2017. 360 с.

Dimova A, Rohova M, Atanasova E, Kawalec P, Czok K. Drug Policy in Bulgaria. Value Heal Reg Issues. 2017 Sep;13:50–4.




DOI: http://dx.doi.org/10.14748/hem.v19i4.7398

Refbacks

Font Size


|